QUECTEL-WIRELESS
21.6.2022 14:02:48 CEST | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has announced its dual-band multi-constellation GNSS module LC29H . Built using the Airoha AG3335 platform, the LC29H is available in multiple variants and optionally integrates RTK and DR. The LC29H series offers high performance, power-efficient solutions to meet market needs of high-precision positioning at the centimeter and decimeter levels. These modules are perfectly suited to an expanding market for autonomous lawn mowers, drones, precision agriculture, micro-mobility scooters and delivery robots as well as other industrial and autonomous applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220621005631/en/
“High precision positioning with centimeter level accuracy is becoming increasingly vital for many new IoT applications. Robotics, UAV and industrial applications needing precise navigation are driving new market requirements and we are very excited to launch our newest generation of high-precision positioning modules,” said Patrick Qian, CEO of Quectel. “With our focus of providing best-in-class, easy-to-use and affordable solutions to our customers, we believe the IoT market is ready for mass adoption of cm-level positioning modules for a wide range of scenarios.”
The LC29H concurrently receives and processes signals from all constellations (GPS, GLONASS, BeiDou, Galileo and QZSS), which in combination with the support of SBAS maximizes satellite signal availability. The module supports L1 and L5 dual-band signal reception, thereby ensuring that terminals can speed up convergence time, improve positioning accuracy, and achieve fast response times even when the signal is interrupted. The dual band design significantly mitigates the multipath effect experienced near high-rise buildings or in deep urban canyons, and provides reliable positioning performance.
In addition, some versions contain 6-axis IMU inertial sensors (3-axis accelerometer + 3-axis gyroscope), and integrate RTK and DR positioning algorithms, allowing for continuous lane-level accurate positioning in scenarios where the satellite signal is partially or completely blocked, such as underground parking lots, tunnels, urban-canyons or forests. When the satellite signal is re-acquired, the LC29H combines inertial sensor data with GNSS signals, and the integrated navigation can provide fast convergence times and decimeter level positioning accuracies.
In order to improve the performance when used with a passive Antenna, the LC29H has a built-in LNA and an internal SAW filter, ensuring high sensitivity and excellent positioning accuracy.
The LC29H adopts a 12nm process, dual-frequency receiver chip and advanced low-power management, thereby enabling low-power GNSS sensing and position fixing. This makes the module an ideal solution for power-sensitive and battery-powered devices including handheld devices, asset trackers, and shared vehicles.
Featuring an LCC form factor and an industry standard footprint size of 12.2 mm × 16.0 mm × 2.5 mm, the LC29H series design allows for easy system integration and smooth migration of legacy designs to the latest high precision GNSS technologies.
The LC29H is available in four product variants each targeting different application scenarios. The LC29H(EA) offers a perfect solution for a growing market of agricultural drones as well as electricity power detection terminals, and is able to improve the anti-interference capability of complex systems. The LC29H(BA) is well suited to agricultural machinery and specialized vehicles, and the LC29H(DA) can enable centimeter-level accuracy in connected lawnmowers and safety helmets at competitive cost.
Additionally, the LC29H can be bundled with Quectel’s wide range of off-the-shelf and customized GNSS antennas . Both passive and active antennas are provided to satisfy customer requirements for high precision positioning. Customized connector types and cable lengths are available as along with comprehensive antenna design support including simulation and testing services. The manufacturing of customized antenna solutions is also available to fast track customer product development.
The LC29H will be showcased at Embedded World Nuremberg on Booth No 171, Hall 5, June 21- 23 2022.
About Quectel:
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS and WiFi/BT modules, antennas and IoT connectivity. Listed on the Shanghai Stock Exchange (603236.SS), our international leadership is devoted to advancing IoT across the globe.
For more information: www.Quectel.com
, LinkedIn
, Facebook
, and Twitter
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005631/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
